Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
Jessica Ley(Washington University in St. Louis), D. Adkins, Barry A. Siegel(Washington University in St. Louis), D. I. Kuperman, T. Rachocki, George Ansstas(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), J. Subramanian, J. Mathai, F. Dehdashti
Cited by 0
Related Papers
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
|The Lancet|2024|729
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter
|Neuro-Oncology|2022|508
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
|JAMA Oncology|2022|411
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
|Clinical Cancer Research|2020|372
Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer
|Journal of Thoracic and Cardiovascular Surgery|2003|301